Finn forfatter "Eriksen, Erik F"
-
Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial Eriksen, Erik F; Chapurlat, Roland; Boyce, Rogely Waite; Shi, Yifei; Brown, Jacques P; Horlait, Stéphane; Betah, Donald; Libanati, Cesar; Chavassieux, Pascale (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)The bone-forming agent romosozumab is a monoclonal antibody that inhibits sclerostin, leading to increased bone formation and decreased resorption. The highest levels of bone formation markers in human patients are observed ...
-
Stunes, Astrid K; Westbroek, Irene; Gustafsson, Björn I; Fossmark, Reidar; Waarsing, Jan H; Eriksen, Erik F; Petzold, Christiane; Reseland, Janne E; Syversen, Unni (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2011)Background Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. ...